Lactococcus lactis

Septerna Appoints Industry Veterans Bernard Coulie, M.D., Ph.D., and Shalini Sharp to its Board of Directors

Retrieved on: 
火曜日, 2月 6, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, McKinsey & Company, Shalini, Bristol Myers Squibb, Lactococcus lactis, Harvard University, Organon, Agenus, Patient, GPCR, Drug discovery, MBA, Endocrinology, Neurocrine Biosciences, Therapy, Assistant, Drug development, Hypoparathyroidism, Acquisition, Goldman Sachs, G protein-coupled receptor, Metabolism, University, Mirati Therapeutics, PTH1R, Precigen, Pharmacy, Internal medicine, Pharmaceutical industry

Dr. Coulie and Ms. Sharp bring deep drug development and company-building experience to Septerna’s board.

Key Points: 
  • Dr. Coulie and Ms. Sharp bring deep drug development and company-building experience to Septerna’s board.
  • Shalini brings a wealth of strategic, financial, and operational experience, having led or advised several successful private and public biotech companies.
  • Bernard Coulie brings more than two decades of senior leadership experience and drug development expertise to the Septerna board.
  • Shalini Sharp has been in the life sciences industry for over 25 years, having spent 14 years as a Chief Financial Officer.

Kirin iMUSE Immune Care and Healthya Visceral Fat Down will go on sale on Tuesday, November 28!

Retrieved on: 
月曜日, 11月 27, 2023
Retail, Health, Fitness & Nutrition, General Health, Vitamins, Supplements, Food, Beverage, Biotechnology, Sale, Capsule, PubMed, Lactococcus lactis, Immunity, Research, Immune system, Kao Corporation, Plasma, Coffee, Government, Polyphenol, Multimedia, Christian democracy, Consumer Affairs Agency, Kirin, Invention, University, BMI, Imperial, Kirin Holdings, IMUSE, Human, Lipid metabolism, Growth, Holding company, Chlorogenic acid, Vaccine, Dietary supplement, Medical device

Kirin Holdings Company, Limited (TOKYO:2503) will launch a dual-care functional food supplement Kirin iMUSE Immuno-Care and Healthya Visceral Fat Down on November 28 (Tuesday).

Key Points: 
  • Kirin Holdings Company, Limited (TOKYO:2503) will launch a dual-care functional food supplement Kirin iMUSE Immuno-Care and Healthya Visceral Fat Down on November 28 (Tuesday).
  • This product is a collaboration between Kirin iMUSE, Japan’s first*1 immune care brand, and Kao Healthya, Japan’s first*1 body fat care beverage brand from Kao Corporation (TOKYO:4452), and will be sold at drugstores nationwide and through Kirin Kyowa Hakko Bio mail order.
  • We are developing a broad lineup of functional food products with immune function claims to help customers solve their health issues.
  • “Kirin iMUSE Immunity Care and Healthya Visceral Fat Down,” which is about to go on sale, is a product born from the joint research project.

Kyowa Hakko's IMMUSE™ Postbiotic Wins Inaugural "Microbiome Modulation" Industry Award

Retrieved on: 
金曜日, 7月 14, 2023
Drink, Powder, Lactococcus lactis, Clinical trial, Christian democracy, NK, MBA, Cell, RD, Doctor of Philosophy, PDC, Audio and Radio Industry Awards, Kyōwa, Capsule, Kyowa Kirin, Food and Drug Administration, Immune system, Ingredient, Food, Disease, Pharmaceutical industry, Vaccine, Plasma

NEW YORK, July 14, 2023 /PRNewswire-PRWeb/ -- Kyowa Hakko USA is thrilled to announce that our groundbreaking product, IMMUSE™ postbiotic for immune health, has been honored as the inaugural recipient of the the Ingredient of the Year: Microbiome Modulation category in the esteemed annual awards by NutraIngredients-USA.

Key Points: 
  • Kyowa Hakko's IMMUSE™ Postbiotic Wins Inaugural "Microbiome Modulation" Industry Award.
  • IMMUSE™ is a clinically researched Lactococcus lactis strain Plasma (LC-Plasma) that uniquely activates the immune system and plasmacytoid dendritic cells (pDCs) to support healthy days*.
  • Thirty published studies, including 15 human trials, support IMMUSE™'s novel mechanism of action.
  • Kyowa Hakko's parent company, Kirin Holdings Co., Ltd. discovered IMMUSE™'s unique mechanism of action.

Nagasaki University Presented Results Of a Specified Clinical Trial On The Use of L. lactis strain Plasma For Patients With COVID-19

Retrieved on: 
木曜日, 5月 11, 2023
Science, Research, Pharmaceutical, Health, COVID-19, University, Education, Clinical Trials, Vaccine, First Department, Smell, Kirin Holdings, Food, Anosmia, Rotavirus, Shortness, Headache, SARS-CoV-2, PDC, Consumer Affairs Agency, Clinical trial, Infection, Division, Multimedia, Chest pain, Fatigue, Lactococcus lactis, Pandemic, Patient, Patent, Risk, Fever Dream, Immune system, Internal medicine, Randomized controlled trial, Blood, Viral load, Shortness of breath, Nagasaki University, Cough, Respiratory Medicine, Institute for Plasma Research, Safety, Pharmaceutical industry, Copper, Omicron, Kirin, Anorexia nervosa, Dysgeusia, Limited, Immunity, Lactococcus, Plasma

Nagasaki University presented the results of a specified clinical trial on patients with COVID-19 using Lactococcus.

Key Points: 
  • Nagasaki University presented the results of a specified clinical trial on patients with COVID-19 using Lactococcus.
  • lactis strain Plasma*1 (L.lactis Plasma, a postbiotic), researched and developed by Kirin Holdings Company, Limited (Kirin Holdings).
  • Nagasaki University and Kirin Holdings have jointly filed a patent application for the findings of this specified clinical trial.
  • Nagasaki University and Kirin hope that L. lactis Plasma will become one of the new treatment or adjunctive care to patients with mild COVID-19.

Second Genome Presents New Preclinical Data for SG-5-00455, Potential First-in-Class Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD), at the 17th Congress of European Crohn's and Colitis Organization (ECCO)

Retrieved on: 
金曜日, 2月 18, 2022
Inflammatory bowel disease, Wound healing, Patient, Lactococcus lactis, Food, Cancer, Biomarker, IBD, Data science, Company, Role, Gene expression, Congress, Arena Pharmaceuticals, KOL, Clinical trial, Precision medicine, Gastroenterology, DRS, CRISPR, Biotechnology, ECCO, FDA, Population, Food and Drug Administration, Gilead, EST, Gilead Sciences, Inflammation, Genome, Program, DOP, Industry, Drug development, Second Genome, PAI, Pharmaceutical industry, IND

Results also demonstrate strong precision medicine potential to identify the target patient population using PAI-1/2 pathway biomarker(s).

Key Points: 
  • Results also demonstrate strong precision medicine potential to identify the target patient population using PAI-1/2 pathway biomarker(s).
  • "We are developing SG-5-00455 as a potential first-in-class precision therapeutic with broad application for IBD patients with disrupted intestinal mucosal healing.
  • This pathway will provide the basis for a potential biomarker to identify patients likely to respond to SG-5-00455.
  • We also hold a strategic collaboration with Arena Pharmaceuticals to identify microbiome biomarkers associated with clinical response for their lead program in gastroenterology, etrasimod.

Second Genome Nominates Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD)

Retrieved on: 
木曜日, 2月 10, 2022
CRISPR, Industry, PAI, Gilead, Biomarker, Role, Virtual, Inflammatory bowel disease, Company, Cancer, ECCO, DOP, KOL, Clinical trial, Data science, FDA, Patient, Food and Drug Administration, Arena Pharmaceuticals, EST, Genome, Biotechnology, Second Genome, Gastroenterology, IBD, Drug development, Food, Doctor of Philosophy, Congress, Artic, Gilead Sciences, Lactococcus lactis, Pharmaceutical industry, IND

"We are excited to be moving SG-5-00455, our development candidate for the treatment of IBD, one step closer to patients.

Key Points: 
  • "We are excited to be moving SG-5-00455, our development candidate for the treatment of IBD, one step closer to patients.
  • With its PAI-1/2 inhibition mechanism of action, we are targeting a well validated pathway that has been shown to play an important role in the pathophysiology of IBD.
  • Second Genome is a biotechnology company that leverages its proprietary technology-enabled platform to discover and develop transformational precision therapies based on novel microbial genetic insights.
  • Second Genome is advancing lead programs in IBD and cancer into IND-enabling studies.

Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China

Retrieved on: 
金曜日, 1月 28, 2022
Lynx, Aurealis, Growth, IND, CEO, Patient, Therapy, Graft-versus-host disease, FGF2, CSF1, GMO, FMT, Inflammation, Board, Human microbiome, Partnership, Granulation tissue, Prevalence, Growth factor, DFU, IL4, Company, Interleukin, Lactococcus lactis, Drug development, Blood, Mouth ulcer, Synthetic biology, LBP, Diabetic foot ulcer, Scholarship, Pharmaceutical industry, Vaccine

"At Aurealis we develop truly novel GMO cell and gene therapies to improve the lives of millions of patients worldwide.

Key Points: 
  • "At Aurealis we develop truly novel GMO cell and gene therapies to improve the lives of millions of patients worldwide.
  • We are extremely excited to collaborate with Aurealis to bring AUP-16 to DFU and other chronic wound patients in China.
  • Company's lead clinical asset is AUP-16, the first-in-class four-in-one cell and gene therapy drug for chronic wounds and other inflammatory degenerative diseases.
  • In June of 2021, Xbiome obtained IND approval in US for its lead program XBI-302, an orally administered FMT therapy for graft-versus-host disease (GvHD).

Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China

Retrieved on: 
金曜日, 1月 28, 2022
Lynx, Aurealis, Growth, IND, CEO, Patient, Therapy, Graft-versus-host disease, FGF2, CSF1, GMO, FMT, Inflammation, Board, Human microbiome, Partnership, Granulation tissue, Prevalence, Growth factor, DFU, IL4, Company, Interleukin, Lactococcus lactis, Drug development, Blood, Mouth ulcer, Synthetic biology, LBP, Diabetic foot ulcer, Scholarship, Pharmaceutical industry, Vaccine

"At Aurealis we develop truly novel GMO cell and gene therapies to improve the lives of millions of patients worldwide.

Key Points: 
  • "At Aurealis we develop truly novel GMO cell and gene therapies to improve the lives of millions of patients worldwide.
  • We are extremely excited to collaborate with Aurealis to bring AUP-16 to DFU and other chronic wound patients in China.
  • Company's lead clinical asset is AUP-16, the first-in-class four-in-one cell and gene therapy drug for chronic wounds and other inflammatory degenerative diseases.
  • In June of 2021, Xbiome obtained IND approval in US for its lead program XBI-302, an orally administered FMT therapy for graft-versus-host disease (GvHD).

Betterbrand and Kyowa Hakko Partner to Develop First-of-Its-Kind Gummy for Respiratory Health With IMMUSE™ LC-Plasma

Retrieved on: 
月曜日, 12月 20, 2021
Kyōwa, NK, Immunity, Kyowa Hakko Kirin, Eurofins Scientific, Science, CEO, Lactococcus lactis, Safety, Immune system, Pharming, GLOBE, Partnership, Christian democracy, Frost, Vaccine

IMMUSE is a postbiotic developed by Kyowa Hakko and was recently awarded the Frost & Sullivan 2021 North American Immune Health Ingredient and New Product Innovation Award .

Key Points: 
  • IMMUSE is a postbiotic developed by Kyowa Hakko and was recently awarded the Frost & Sullivan 2021 North American Immune Health Ingredient and New Product Innovation Award .
  • "We base everything we do in science," says Dr. Chris Jackson, Pharm.D, founder and CEO of Betterbrand.
  • "Partnering with an award-winning global ingredient manufacturer like Kyowa increases consumer confidence in both the effectiveness and safety of our health supplements."
  • "We're excited to partner with Betterbrand and for this opportunity to incorporate IMMUSE as part of its newest line of gummies," said Mary Murphy, Sales Manager at Kyowa Hakko USA.

Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™

Retrieved on: 
火曜日, 9月 21, 2021
Drink, Achievement, ROI, Cheese, Fatigue, Health, Immunity, Kirin Holdings, Functional food, Overalls, Frost & Sullivan, Lactococcus lactis, Christian democracy, Immune system, Immunology, The Non-GMO Project, PDC, Acquisition, NK, Leadership, GRAS, Kyowa Hakko Kirin, Yogurt, Research, Industry, Probiotic, Vaccine, Pharmaceutical industry

SANTA CLARA, Calif., Sept. 21, 2021 /PRNewswire/ -- Based on its recent analysis of the North American immune health ingredient market, Frost & Sullivan recognizes Kyowa Hakko USA, Inc. (Kyowa Hakko) with the 2021 North American New Product Innovation Award for its clinically backed, patented, non-GMO, allergen-free paraprobiotic, IMMUSE™, Lactococcus lactis strain plasma (LC-Plasma),). The lactic acid bacteria developed by Kirin Holding Company Limited and offered by Kyowa Hakko USA, directly activates immune cells to provide comprehensive innate and adaptive immune support. IMMUSE™  provides ease of formulation and can be used in a number of products including drinks, yogurt, gummies and range of other functional food and beverages.

Key Points: 
  • The lactic acid bacteria developed by Kirin Holding Company Limitedand offered by Kyowa Hakko USA, directly activates immune cells to provide comprehensive innate and adaptive immune support.
  • Other immune support ingredients, including generic probiotics and beta-glucan, activate limited immune cell types, imparting only partial immune support compared to IMMUSE.
  • Dr. Shintaro Ichikawa, Director of Technical Affairs at Kyowa Hakko USA, led the development and product launch of IMMUSE notes, "IMMUSEis unlike any other immune support ingredient, by activating pDC's, key leaders of the immune system,IMMUSEprovides more comprehensive immune support."
  • It is an honor to have our innovative Kyowa Hakko clinically-studied ingredient recognized to elevate immune health products."